Publication: Vonoprazan versus proton-pump inhibitors for gastric endoscopic submucosal dissection-induced ulcers: A systematic review and meta-analysis
3
item.page.dc.date.issued
2018-12-01
item.page.dc.type
item.page.dc.identifier.issn
14735687
0954691X
0954691X
item.page.dc.identifier.doi
item.page.dc.identifier.other
2-s2.0-85056265944
item.page.dc.rights
Mahidol University
item.page.dc.rights.holder
SCOPUS
item.page.dc.identifier.citation
European Journal of Gastroenterology and Hepatology. Vol.30, No.12 (2018), 1416-1421
punsarn.item.page.citation
Veeravich Jaruvongvanich, Kittika Poonsombudlert, Patompong Ungprasert Vonoprazan versus proton-pump inhibitors for gastric endoscopic submucosal dissection-induced ulcers: A systematic review and meta-analysis. European Journal of Gastroenterology and Hepatology. Vol.30, No.12 (2018), 1416-1421. doi:10.1097/MEG.0000000000001204 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/46156
Research Projects
Organizational Units
Authors
Journal Issue
relationships.isThesisOf
item.page.dc.title
Vonoprazan versus proton-pump inhibitors for gastric endoscopic submucosal dissection-induced ulcers: A systematic review and meta-analysis
item.page.dc.contributor.author
item.page.dc.description.abstract
© 2018 Wolters Kluwer Health, Inc. All rights reserved. Acid secretion inhibitors are usually prescribed to promote the healing of artificial ulcers caused by endoscopic submucosal dissection (ESD) to reduce the risk of gastric perforation and delayed bleeding. Vonoprazan is a newer agent that has been shown to be more potent than a proton-pump inhibitor (PPI). However, it remains unclear whether vonoprazan is more effective than PPI in promoting healing of ulcers caused by ESD. Medline and Embase databases were searched through January 2018 for studies that compared the rate of complete healing of ulcers caused by ESD and post-ESD delayed bleeding in patients who received vonoprazan versus those who received PPI after ESD. Pooled odds ratio (OR) and 95% confidence interval (CI) were calculated using a random-effect model, generic inverse variance method. The between-study heterogeneity was quantified using the Q-statistic and I 2. A total of six studies consisting of 461 patients were identified. The likelihood that ulcers caused by ESD were completely healed at 4-8 weeks after the procedure was significantly higher among patients who received vonoprazan compared with those who received PPI, with a pooled OR of 2.27 (95% CI=1.38-3.73; I 2 =0%). The risk of developing post-ESD delayed bleeding was also numerically lower among those who received vonoprazan, with a pooled OR of 0.79, although the result did not reach statistical significance (95% CI=0.18-3.49; I 2 =29%). This study found that patients who received vonoprazan after ESD had a significantly higher rate of completely healed ulcers compared with those who received PPI.